

Atopic Dermatitis & Prurigo Nodularis Patient Enrollment and Prescription

	e to our pharmacy at "GENTRY HEALTH SERVICES" in Avon Lake, Ohio.
PATIENT INFORMATION	PRESCRIBER INFORMATION
Patient Name	
DOB// SSN Gender Weight Height Phone	
Address	
City, State, Zip	
Cell Phone E-Mail	Phone Fax
PLEASE PROVIDE COPY OF PATIENT'S PRESCRIPTION INSURANCE CARD WITH ENROLLMENT FORM	Office Contact Person
Insurance Co. Name	Office Contact EMAIL
Insurance Co. Phone Group#	Prescription Date Date Needed
Policy Holder Name	With my signature on this form, I also authorize use of Gentry Health's Services
Policy Holder Employer	which includes serving as my prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.
Relationship to Patient	
ID# RxBIN PCN	Ship to: □Patient □Prescriber's Office □Discount Drug Mart
PLEASE PROVIDE ALL RELEVANT CHART NOTES FOR INSURANCE PURPOSES	
Medical Information (DO NOT COMPLETE IF CHART NOTES ARE PROVIDED)	
Diagnosis ICD-1	
Date of Diagnosis Body Surface Affected:	1996
# of Nodules: □ ≥ 20 Itch NRS (0 -10):	M /M
□ Patient has moderate to severe atopic dermatitis (AD) that is inadequately	
controlled on prior or current topical therapy	
Drug Allergies Latex Alle	ergy? OYES ONO
Failed Prior therapies?	1/1/2/11
☐ Topical Corticosteroids:	@ [Y] @ O O [] U []
- <u></u>	to \ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Topical therapy not appropriate	
Reason:	
☐ Systemic Corticosteriods, Immunosupressants and/or Pho	
	to
	to
Systemic corticosteroids not appropriate	□ Scalp □ Groin □ Nails □ Face
 Immunosuppressants not appropriate Phototherapy not appropriate 	Other:
Reason:	
Does the patient have history of conjunctivitis or keratitis? □YES □NO	
Additional Comments	
PRESCRIPTION INFORMATION (please indicate days supply if different than suggested days supply)	
□ Adbry® (tralokinumab-ldrm) □ 150mg Pre-filled Syring	
□ ADULT DOSING: 600MG SQ at week 0 and 300MG e □ PEDIATRIC DOSING: 300MG at week 0 and 150MG e	
□ Cibinqo TM (abrocitinib) □ 50mg Tablet □ 100 m Directions:Take 1 tablet daily	ng Tablet
□ Dupixent® (dupilumab) □ Syringe □ Pen	Qty. 50 tablets Refills
□ ADULT STARTER: 600MG SQ at week 0, 300MG SQ	at weeks 2 & 4 Quantity:4 Refills
□ ADULT MAINTENANCE: 300MG SQ once every 2 wee	
☐ PED (up to 5yr) 5-14kg: 200MG SQ every 4 weeks	
☐ PED (up to 5yr) 15-29kg: 300MG SQ every 4 weeks	
☐ PED (6-17 yrs) 15-29kg: 600MG SQ week 0, 300mg	
□ PED (6-17 yrs) 30-59kg: <u>400MG SQ week 0, 200mg</u>	
☐ PED (6-17 yrs) ≥ 60kg: <u>600MG_SQ_week_0, 300mg_Q</u>	
☐ EBGLYSS™ (lebrikizumab-lbkz) ☐ 250mg/2mL Pre-Fille	
□ INITIAL DOSE: <u>500MG SQ at week 0 and week 2</u>	Quantity: Refills
□ INDUCTION DOSE: 250 MG SQ every 2 weeks until w	
MAINTENANCE DOSE: 250MG SQ every 4 weeks	Quantity: Refills
□ NEMLUVIO® (nemolizumab-ilto) 30mg Prefilled Pen □ Prurigo Nodularis < 90kg: 60 mg, followed by 30mg gi	ven q4wks Quantity: Refills
Prurigo Nodularis < 90kg. 60 mg, followed by 50mg gi	
☐ Atopic Dermatitis: 60 mg, followed by 30mg given q4w	vks Quantity: Refills
OPZELURA™ 1.5% Cream 60 GM Tube	
Directions: Apply thin layer twice daily to affected areas (up to 20% BSA) MAX 60 gm/wk. Qty:tube(s) Refills	
□ Rinvoq® (upadacitinib) □ 15mg ER Tablet □ 30mg Directions: Take 1 tablet daily	ER Tablet Oty: 30 tablets Refills
UVTAMA® (tapinarof) cream 60 gram tube	
Directions: Apply a thin layer of VTAMA cream to affected a	reas once daily Quantity Tube(s) Refills